Emster Kurt von - 29 Sep 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Role
Director
Signature
/s/ Paul Quinlan, as attorney-in-fact for Kurt von Emster
Issuer symbol
N/A
Transactions as of
29 Sep 2023
Net transactions value
-$170,070
Form type
4
Filing time
29 Sep 2023, 17:54:02 UTC
Previous filing
08 Jun 2023
Next filing
26 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $79,605 +15,921 +18% $5.00 105,921 29 Sep 2023 Direct
transaction CBAY Common Stock Sale $249,675 -15,921 -15% $15.68 90,000 29 Sep 2023 Direct F1, F2
holding CBAY Common Stock 18,406 29 Sep 2023 By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -6,357 -100% $0.000000* 0 29 Sep 2023 Common Stock 6,357 $5.00 Direct F4
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -943 -100% $0.000000* 0 29 Sep 2023 Common Stock 943 $5.00 Direct F5
transaction CBAY Stock Appreciation Right Options Exercise $0 -3,372 -100% $0.000000* 0 29 Sep 2023 Common Stock 3,372 $5.00 Direct F6
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -5,249 -100% $0.000000* 0 29 Sep 2023 Common Stock 5,249 $5.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 30, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $15.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This corrects a typographical error made in the reporting person's previous Form 4 filings. In filings between October 2, 2017 and March 17, 2018 (inclusive) the reporting person reported 17,236 shares held indirectly rather than the 17,326 shares that the reporting person actually held indirectly (and had reported previously). After adding 1,080 shares on June 5, 2018 the reporting person incorrectly reported in a filing on June 7, 2018 and in filings thereafter owning 18,316 shares indirectly rather than the 18,406 shares that the reporting person actually held indirectly.
F4 The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.
F5 The option vested as to 1/4 of the underlying shares on April 2, 2010 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.
F6 The incentive award (the "Award") was granted under the CymaBay 2013 Equity Incentive Plan and could be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The shares subject to the Award vested in 48 equal monthly installments from the grant date.
F7 The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.